Metabolic dysfunction-associated steatohepatitis, or MASH, is gaining attention across the medical community, but for many patients it remains a largely silent disease. Closely linked with obesity, type 2 diabetes and other cardiometabolic risk fa...
15 April 2025, The NetherlandsJulius Clinical’s Scientific Officer, Associate Professor Manuel Castro Cabezas, interviewed Professor Liesbeth van Rossum, internist-endocrinologist and professor in the field of obesity at the Erasmus MC, Univ...
A paper published in Clinical Rheumatology from the research group of our Scientific Officer Manuel Castro Cabezas and Chief Scientific Officer Rick Grobbee indicates that patients with rheumatoid arthritis with high liver fibrosis scores are like...
11 February 2025Professor Rick Grobbee, Professor of Clinical Epidemiology at the Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht (the Netherlands), and Chief Scientific Officer at Julius Clinical, (Academ...
Commentary by Dr. Marco Alings, MD PhD, Amphia Ziekenhuis, Breda; WCN, Utrecht; Scientific Officer at Julius ClinicalThere is a strong association between age, obesity, liver fibrosis and cardiovascular (CV) disease, particularly in the conte...
"*" indicates required fields
"*" indicates required fields
